Aegis Capital Boosts PT on Catalyst (CPRX) to $4 Following Equity Raise
Tweet Send to a Friend
Aegis Capital maintains its buy rating on Catalyst Pharmaceutical (Nasdaq: CPRX), but boosted its 12-month price target from $3.50 up ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
